Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | UCHL5 | Q9Y5K5 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27670310 | 0.86 | CES2 (0.43) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17459279 | 0.78 | DAO (0.47) | HPGDDAOCES2CES1WRN | |
| SCHEMBL4632227 | 0.78 | CYP2C9 (0.54) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27484445 | 0.76 | CYP2C9 (0.53) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4240529 | 0.76 | DAO (0.45) | CYP2C9CYP2D6CYP2C19DRD3DAO | |
| SCHEMBL15240160 | 0.76 | ALDH1A1 (0.43) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1678767 | 0.76 | DAO (0.41) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7759137 | 0.74 | CYP2C9 (0.65) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23350351 | 0.74 | ALDH1A1 (0.37) | HPGDDAOCES2CES1WRN | |
| SCHEMBL10331392 | 0.74 | KMT2A (0.38) | CYP2C9HPGDCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1888566-A1 | 2-[(ISOQUINOLIN-3-CARBONYL)AMINO]-PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | Transtech Pharma, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006093823-A9 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA INC (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006093823-A1 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | APPLIED NANOSYSTEMS B.V. (NL) | 2005-12-08 | — | — | US | disclosed |
| EP-1350507-A1 | Delivery of a substance to a pre-determinated site | Applied NanoSystems B.V. (NL) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003044008-A1 | LIGHT-SWITCHABLE GELATOR | APPLIED NANOSYSTEM B.V. (NL) | 2003-05-30 | — | — | WO | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | TACR1, TACR2, NPSR1 | CYP2C9 1723/4885HPGD 2027/4885CYP3A4 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.